Track topics on Twitter Track topics that are important to you
AstraZeneca plc (AZN.L, AZN) and MedImmune, its global biologics research and development arm, said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation for Imfinzi (durvalumab) for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer or NSCLC whose disease has not progressed following platinum-based chemoradiation therapy.
Original Article: AstraZeneca: FDA Grants Breakthrough Therapy Designation For ImfinziNEXT ARTICLE
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009. it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...